Cargando…

Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification and Immunotherapy

Triple negative breast cancer (TNBC) has negative expression of ER, PR and HER-2. TNBC shows high histological grade and positive rate of lymph node metastasis, easy recurrence and distant metastasis. Molecular typing based on metabolic genes can reflect deeper characteristics of breast cancer and p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Yu, Che, Yingqi, Fu, Zhongze, Zhang, Henan, Wu, Huiyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Public Health
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296841/ https://www.ncbi.nlm.nih.gov/pubmed/35875026 http://dx.doi.org/10.3389/fpubh.2022.902378

Ejemplares similares

Neighborhood Social Determinants of Triple Negative Breast Cancer
por: Hossain, Fokhrul, et al.
Publicado: (2019)

Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors
por: Prakash, Om, et al.
Publicado: (2020)

Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis
por: Liu, Xiaoyan, et al.
Publicado: (2021)

Assessing Real-World Racial Differences Among Patients With Metastatic Triple-Negative Breast Cancer in US Community Practices
por: Tan, Ruoding, et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Racial and regional disparities of triple negative breast cancer incidence rates in the United States: An analysis of 2011–2019 NPCR and SEER incidence data
por: Zhang, Wei, et al.
Publicado: (2022)

Prospects of Immunotherapy for Triple-Negative Breast Cancer
por: Qiu, Dan, et al.
Publicado: (2022)

Research on the Dynamic Feedback Mechanism of Fiscal Policy Regulation Under COVID-19: Evidence From China
por: Wang, Shu, et al.
Publicado: (2022)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Immunotherapy for the Treatment of Triple-Negative Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2022)

Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Breast Cancer Detection and Classification Empowered With Transfer Learning
por: Arooj, Sahar, et al.
Publicado: (2022)

Research on Monetary Policy Implementation and Industrial Structure Transformation Under COVID-19—Evidence From Eight Economic Zones in Mainland China
por: Zhou, Baicheng, et al.
Publicado: (2022)

Multichannel DenseNet Architecture for Classification of Mammographic Breast Density for Breast Cancer Detection
por: Pawar, Shivaji D., et al.
Publicado: (2022)

Molecular Classification of Triple-Negative Breast Cancer
por: Ahn, Sung Gwe, et al.
Publicado: (2016)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
por: Wesolowski, Jakub, et al.
Publicado: (2022)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
por: Luo, Chenyi, et al.
Publicado: (2022)

Correction: Advances in immunotherapy for triple-negative breast cancer
por: Liu, Yang, et al.
Publicado: (2023)

Immunotherapy in triple negative breast cancer: beyond checkpoint inhibitors
por: Abdou, Yara, et al.
Publicado: (2022)

A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

Enhanced Therapeutic Efficacy of Combining Losartan and Chemo-Immunotherapy for Triple Negative Breast Cancer
por: Zhao, Qing, et al.
Publicado: (2022)

Association between maternal shift work during pregnancy child overweight and metabolic outcomes in early childhood
por: Liao, Che-Wei, et al.
Publicado: (2022)

HDAC inhibition potentiates immunotherapy in triple negative breast cancer
por: Terranova-Barberio, Manuela, et al.
Publicado: (2017)

Recent advances in triple negative breast cancer: the immunotherapy era
por: Marra, Antonio, et al.
Publicado: (2019)

Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer
por: Mediratta, Karan, et al.
Publicado: (2020)

Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer
por: Llinàs-Arias, Pere, et al.
Publicado: (2021)

Research progress on immunotherapy in triple-negative breast cancer (Review)
por: Zhang, Xiaoxiao, et al.
Publicado: (2022)

Triple negative breast cancer: Immunogenicity, tumor microenvironment, and immunotherapy
por: Loizides, Sotiris, et al.
Publicado: (2023)

Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer
por: Jacobs, Flavia, et al.
Publicado: (2023)

Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
por: Zheng, Yiwen, et al.
Publicado: (2023)

Spatial predictors of immunotherapy response in triple-negative breast cancer
por: Wang, Xiao Qian, et al.
Publicado: (2023)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
por: Alečković, Maša, et al.
Publicado: (2023)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Correction for: A novel fatty-acid metabolism-based classification for triple negative breast cancer
por: Yang, Xia, et al.
Publicado: (2023)

Immune Classification and Immune Landscape Analysis of Triple-Negative Breast Cancer
por: Hu, Shaojun, et al.
Publicado: (2021)

Survey on practice of venom immunotherapy in France
por: Dzviga, Charles, et al.
Publicado: (2016)

Classification of triple-negative breast cancers based on Immunogenomic profiling
por: He, Yin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8ldblic1pvccsu5euoor0pllqo